



Aspartate aminotransferase to platelet ratio index for the assessment of liver fibrosis severity in patients with chronic hepatitis

Roxana Sirli^{1*}, Ioan Sporea²

¹Department of Gastroenterology, University of Medicine and Pharmacy, Timisoara, Romania

²Department of Hepatology, University of Medicine and Pharmacy, Timisoara, Romania

ARTICLE INFO

Article Type:

Letter to Editor

Article history:

Received: 09 Apr 2011

Revised: 12 Apr 2011

Accepted: 15 Apr 2011

Keywords:

Aspartate aminotransferase

Liver fibrosis

Chronic hepatitis

Please cite this paper as:

Sirli R, Sporea I. Aspartate aminotransferase to platelet ratio index for the assessment of liver fibrosis severity in patients with chronic hepatitis. *Hepat Mon.* 2011;11(7): 560-1.

© 2011 Kowsar M.P.Co. All rights reserved.

Dear Editor,

I read with interest the article by Yilmaz *et al.* regarding the value of aspartate aminotransferases (AST)-to-platelet ratio index (APRI score) for the noninvasive assessment of liver fibrosis in chronic hepatitis, which was published in *Hepatitis Monthly* (1). The authors evaluated patients diagnosed with chronic hepatitis C and B and nonalcoholic fatty liver disease (NAFLD) and assessed their APRI scores to predict the presence of fibrosis (Metavir score of at least F1). Most published studies have used acoustic radiation force impulse (ARFI) elastography results as a predictor of significant fibrosis (Metavir score of F \geq 2) and cirrhosis in chronic hepatitis C virus (HCV) infections. A meta-analysis (2) from 2007 proved that with a cut-off value of 0.5, APRI results had 81% sensitivity (Se) and 50% specificity (Sp) in predicting significant fibrosis (Metavir score of F \geq 2) and that with a cut-off value of 1, the Se and Sp for predicting cirrhosis were 76% and 71%, respectively. In a recent meta-analysis that included more than 8,700 patients (3), the summary

of areas under receiver operating characteristic (AUROC) values of APRI for the diagnosis of significant fibrosis, severe fibrosis, and cirrhosis were 0.77, 0.80, and 0.83, respectively. For significant fibrosis, the Se and Sp of an APRI threshold of 0.7 were 77% and 72%, respectively, and the corresponding values obtained with a threshold of 1.0 for severe fibrosis were 61% and 64%, respectively. For cirrhosis, the Se and Sp of an APRI threshold of 1.0 were 76% and 72%, respectively [3]. In the study by Yilmaz *et al.* (1), for an optimal cut-off point of > 0.44, the APRI score was a poor predictor of fibrosis (F \geq 1), with an Se and Sp of 72.7% and 62.4% (AUROC = 0.582), which was expected since all noninvasive tests show poor performance in differentiation of the early stages of fibrosis.

Regarding hepatitis B virus (HBV) infection, a recently published study from China (4) showed that age could be a factor influencing the ARFI threshold that separates patients without fibrosis from those with a Metavir score of at least F1, the cut-off points being 0.11 for patients aged < 35 years and 0.18 for those >35 years. A study from France showed that the APRI values (0.28 vs. 0.43; $P < 0.0001$) were significantly lower in inactive hepatitis B surface antigen (HBsAg) carriers than in patients with chronic HBV infection (5). Although in the study by Yilmaz *et al.* (1) in patients with chronic HBV infection, the APRI score could not help differentiate subjects with

* Corresponding author at: Roxana Sirli, Department of Gastroenterology, University of Medicine and Pharmacy, Timisoara, Romania, P.O. Box: 14, Sirius str., ap.5 300688, Timisoara, Romania. Tel: +40-723537039, Fax: +40-256488003.

E-mail: roxanasirli@gmail.com

Copyright © 2011, BRCCGL, Published by Kowsar M.P.Co. All rights reserved.

a Metavir score of F0 from those with a Metavir score of at least F1, there are other published data showing that APRI can be a valuable predictor of significant fibrosis ($F \geq 2$) and cirrhosis, similar to its predictive value in patients with chronic HCV infection (6), with AUROC values of 0.81 (0.74–0.87) and 0.83 (0.77–0.90), respectively. Few studies have been published regarding the value of APRI in NAFLD, and these studies showed that the APRI values tended to increase with the severity of fibrosis (7, 8). Further studies are required to validate these findings. Overall, considering the wide availability and low cost of performing APRI, we think that it can be a useful tool for the evaluation of fibrosis in patients with chronic hepatitis, possibly in association with other tests, or for repetitive evaluation to assess the progression of fibrosis (9).

References

1. Yilmaz Y, Yonal O, Kurt R, Bayrak M, Aktas B, Ozdogan O. Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease. *Hepat Mon.* 2011;**11**(2):103-7.
2. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. *Hepatology.* 2007;**46**(3):912-21.
3. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. *Hepatology.* 2011;**53**(3):726-36.
4. Liu HB, Zhou JP, Zhang Y, Lv XH, Wang W. Prediction on liver fibrosis using different APRI thresholds when patient age is a categorical marker in patients with chronic hepatitis B. *Clin Chim Acta.* 2011;**412**(1-2):33-7.
5. Castera L, Bernard PH, Le Bail B, Foucher J, Trimoulet P, Merrouche W, et al. Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers. *Aliment Pharmacol Ther.* 2011;**33**(4):455-65.
6. Zhu X, Wang LC, Chen EQ, Chen XB, Chen LY, Liu L, et al. Prospective Evaluation of FibroScan for the Diagnosis of Hepatic Fibrosis Compared with Liver Biopsy/AST Platelet Ratio Index and FIB-4 in Patients with Chronic HBV Infection. *Dig Dis Sci.* 2011; [Epub ahead of print].
7. Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cardenas E, Sanchez-Avila F, Vargas-Vorackova E. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. *Ann Hepatol.* 2008;**7**(4):350-7.
8. Cales P, Laine F, Boursier J, Deugnier Y, Moal V, Oberti F, et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. *J Hepatol.* 2009;**50**(1):165-73.
9. Mummadi RR, Petersen JR, Xiao SY, Snyder N. Role of simple biomarkers in predicting fibrosis progression in HCV infection. *World J Gastroenterol.* 2010;**16**(45):5710-5.